Cingulate Inc. (CING)

NCM – Цена в реальном времени. Валюта: USD

4.79

-0.17 (-3.43%)

При закрытии: May 12, 2026, 4:00 PM EDT

4.95

+0.16 (3.34%)

До открытия: May 13, 2026, 4:56 AM EDT

06.04.2026

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 4Q25

Dallas, Texas--(Newsfile Corp. - April 6, 2026) - Cingulate Inc. (NASDAQ: CING): Stonegate Capital Partners updates their coverage on Cingulate Inc. (NASDAQ: CING). Cingulate's 4Q25 update continues to position CTx-1301 toward a potential commercial ADHD launch, with the regulatory focus now centered on manufacturing (CMC) rather than clinical performance.

16.03.2026

Why did Cingulate stock skyrocket today?

Cingulate Inc (NASDAQ: CING) soared on Monday morning after the US Patent and Trademark Office (USPTO) cleared a key patent application for the firm's “Trimodal, Precision-Time Pulsatile Release Tablet.” This regulatory victory effectively safeguards the proprietary technology behind Cingulate's lead ADHD candidate – CTx-1301 – providing a massive boost to investor confidence as the company prepares for a transformative year.

18.11.2025

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 3Q25

Dallas, Texas--(Newsfile Corp. - November 18, 2025) - Cingulate Inc. (NASDAQ: CING): Stonegate Capital Partners updates their coverage on Cingulate Inc. (NASDAQ: CING). Cingulate's 3Q25 results reflect continued progress toward transforming CTx-1301 into a commercial ADHD franchise.

23.10.2025

Cingulate's Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting

Presentation by ADHD expert Dr. Ann Childress to highlight Phase 3 findings supporting the potential for true, entire active-day symptom control Presentation by ADHD expert Dr. Ann Childress to highlight Phase 3 findings supporting the potential for true, entire active-day symptom control

06.08.2025

Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301

Regulatory filing marks significant milestone for medication designed to provide once-daily, entire active-day symptom control in ADHD patients Regulatory filing marks significant milestone for medication designed to provide once-daily, entire active-day symptom control in ADHD patients

Cingulate Inc. (CING)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Cingulate Inc. (CING)

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 4Q25

Why did Cingulate stock skyrocket today?

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 3Q25

Cingulate's Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting

Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 4Q25

Why did Cingulate stock skyrocket today?

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 3Q25

Cingulate's Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting

Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301

Видео

No Data

Пресс-релизы

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 4Q25

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 3Q25

Cingulate's Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting

Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301

Search stocks

Cingulate Inc. (CING)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Cingulate Inc. (CING)

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 4Q25

Why did Cingulate stock skyrocket today?

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 3Q25

Cingulate's Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting

Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 4Q25

Why did Cingulate stock skyrocket today?

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 3Q25

Cingulate's Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting

Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301

Видео

No Data

Пресс-релизы

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 4Q25

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 3Q25

Cingulate's Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting

Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301